Tag - LNSR

Developments

First patients treated with LENSAR’s ALLY cataract treatment

The first commercial cases of the LENSAR (NASDAQ:LNSR) ALLY Adaptive Cataract Treatment System were performed by Robert Weinstock, M.D. at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted...

August 16, 2022

Developments

LENSAR receives FDA clearance of ALLY Adaptive Cataract Treatment System

The FDA cleared LENSAR’s (NASDAQ:LNSR) next-generation ALLY Adaptive Cataract Treatment System to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery procedure seamlessly in a single...

June 13, 2022

Developments

FDA accepts LENSAR 510(k) submission for ALLY

The FDA accepted a 510(k) submission from LENSAR (NASDAQ:LNSR) for its next-generation ALLY Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY and is the...

March 1, 2022

Markets

BTIG starts LENSAR at buy; PT $15

BTIG launched coverage of LENSAR (NASDAQ:LNSR) with a “buy” rating and $15 price target. The stock closed at $7.10 on Nov. 19. LENSAR is a small-cap technology play on the fast growing laser cataract surgery market. By...

November 22, 2021

Markets

SVB Leerink starts Lensar at OP; PT $20

SVB Leerink initiated coverage of Lensar (NASDAQ:LNSR) with an “outperform” rating and price target of $20. The stock closed at $9.50 on Feb. 23. Lensar was recently spun out from PDL Biopharma and is, “in our view, an...

February 24, 2021

Tag - LNSR

First patients treated with LENSAR’s ALLY cataract treatment

LENSAR receives FDA clearance of ALLY Adaptive Cataract Treatment System

FDA accepts LENSAR 510(k) submission for ALLY

BTIG starts LENSAR at buy; PT $15

SVB Leerink starts Lensar at OP; PT $20

General

More